Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor. ...Middle East

TAIPEI, Oct. 20, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical study in Australia with linvemastat (FP-020), its novel, highly selective, oral...

Hence then, the article about foresee pharmaceuticals announces preliminary results from a phase 1 clinical trial highlighting promising safety tolerability and pharmacokinetic profile of linvemastat fp 020 a novel and selective mmp 12 inhibitor was published today ( Sunday 20/10/2024 - 03:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Announces Preliminary Results from a Phase 1 Clinical Trial, Highlighting Promising Safety, Tolerability and Pharmacokinetic Profile of Linvemastat (FP-020), a Novel and Selective MMP-12 Inhibitor. )

Also on site :

• President Trump Buys DraftKings, Red Rock, Sells Other Gaming Stocks
• Isomer's Brightening Anti-Aging Duo Is Perfect for Women Over 50, and Shoppers Confirm It's 'So Good'
• Nordstrom Rack Has 'Stylish and 'Supportive' Sandals That You'll Want to Wear 'All Day' on Sale for 50% Off